All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Myeloid-Related Proteins (MRPs), S100A8 and S100A9, are members of the S100 calcium-binding protein family. These proteins have been shown to be overly expressed in Acute Myeloid Leukemia (AML) 1 and S100A8 in particular can contribute to poor prognosis in AML patients2. Once secreted, S100A8 and S100A9 induce inflammatory and immune responses via interaction with a range of receptors including Toll-Like Receptor (TLR4)3. The potential functions of S100A8 and S100A9 in the development and progression of leukemia is yet to be elucidated.
Malika Laouedj and colleagues from the Centre de Recherche du CHU de Quebec-Universite Laval, Qubec, Canada published results from their study on the role of S100A8 and S100A9 in AML in Blood on 30 January 2017.4
In this study, the biological functions of S100A8 and S100A9 and its effect on survival were investigated using mouse models of AML as well as cell samples of patients with primary AML.
In summation, S100A9 and S100A8 can regulate myeloid differentiation in AML. S100A9 can induce the differentiation of AML cells via TLR-4 and also prolonged survival with no adverse effects in AML models. Additionally, S100A8 can regulate S100A9 activity and also sustain AML immature phenotypes.
The authors concluded by stating that their study could pave way for an alternative treatment approach aimed at cell differentiation of myelomonocytic and monocyic AMLs. The authors further suggested that a differentiated targeted therapy on the SA1008/SA100A9 and TLR-4 pathway could have a significant impact on the clinical outcomes of AML patients.
S100A8 and S100A9 are calcium-binding proteins predominantly expressed by neutrophils and monocytes, and play key roles in both normal and pathological inflammation. Recently, both proteins were found to promote tumor progression through the establishment of pre-metastatic niches and to inhibit antitumor immune responses. Although S100A8 and S100A9 have been studied in solid cancers, their functions in hematological malignancies remain poorly understood. However, S100A8 and S100A9 are highly expressed in acute myeloid leukemia (AML), and S100A8 expression has been linked to a poor prognosis in AML. We identified a small subpopulation of cells expressing S100A8 and S100A9 in AML mouse models and in primary human AML samples. In vitro and in vivo analyses revealed that S100A9 induces AML cell differentiation, whereas S100A8 prevents differentiation induced by S100A9 activity and maintains AML immature phenotype. Treatment with recombinant S100A9 proteins increased AML cell maturation, induced growth arrest, and prolonged survival in an AML mouse model. Interestingly, anti-S100A8 antibody treatment had effects similar to S100A9 therapy in vivo, suggesting that high ratios of S100A9 over S100A8 are required to induce differentiation. Our in vitro studies on the mechanisms/pathways involved in leukemic cell differentiation revealed that binding of S100A9 to toll-like receptor 4 (TLR4) promotes activation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinases 1 and 2, and Jun N-terminal kinase signaling pathways, leading to myelomonocytic and monocytic AML cell differentiation. These findings indicate that S100A8 and S100A9 are regulators of myeloid differentiation in leukemia and have therapeutic potential in myelomonocytic and monocytic AMLs.
References
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?